AAV gene therapy

Shares of Regenxbio Inc (NASDAQ: RGNX) could have 320 percent upside, according to Piper Jaffray, which has a price target of $33 on the stock. The $33 target price represents a potential upside of 320 percent from Wednesday's close of $7.86. "Regenxbio is a leader in the AAV gene therapy world and...